Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes
Authors
Keywords
-
Journal
Cardiovascular Diabetology
Volume 19, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-10-24
DOI
10.1186/s12933-020-01154-w
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Costs associated with renal and cardiovascular events among patients with type 2 diabetes mellitus and nephropathy: a cost model based on the CREDENCE clinical trial
- (2020) Ameur M. Manceur et al. CURRENT MEDICAL RESEARCH AND OPINION
- Third-Line Antidiabetic Therapy Intensification Patterns and Glycaemic Control in Patients with Type 2 Diabetes in the USA: A Real-World Study
- (2020) Digsu N. Koye et al. DRUGS
- Changes in SGLT2i and GLP-1RA real-world initiator profiles following cardiovascular outcome trials: A Danish nationwide population-based study
- (2020) Jakob S. Knudsen et al. PLoS One
- Use of Glucagon-Like Peptide 1 Receptor Agonists and Risk of Serious Renal Events: Scandinavian Cohort Study
- (2020) Björn Pasternak et al. DIABETES CARE
- Effects of ertugliflozin on renal function over 104 weeks of treatment: a post hoc analysis of two randomised controlled trials
- (2020) David Z. I. Cherney et al. DIABETOLOGIA
- UTILIZATION OF GLUCOSE-LOWERING DRUGS IN PATIENTS WITH T2DM AND ESTABLISHED CVD IN US: A DESCRIPTIVE STUDY USING OPTUM CLINFORMATICS DATA
- (2020) Michael Ganz et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Use of sodium-glucose co-transporter 2 inhibitors and risk of serious renal events: Scandinavian cohort study
- (2020) Björn Pasternak et al. BMJ-British Medical Journal
- The Effect of Glucagon-Like Peptide-1 Receptor Agonists on Renal Outcomes in Type 2 Diabetes
- (2020) Win L. Yin et al. Diabetes Therapy
- Generalizability of sodium-glucose co-transporter-2 inhibitors cardiovascular outcome trials to the type 2 diabetes population: a systematic review and meta-analysis
- (2020) Marco Castellana et al. Cardiovascular Diabetology
- 29-LB: Physicians’ Chronic Kidney Disease (CKD) Awareness over Time in Type 2 Diabetes (T2D)
- (2020) JOHN SCHEMPF et al. DIABETES
- 624-P: Primary Care Education Leads to Improved Diabetes Knowledge and Clinical Practice
- (2020) RYAN WOOLLEY et al. DIABETES
- Prescribing Paradigm Shift? Applying the 2019 European Society of Cardiology–Led Guidelines on Diabetes, Prediabetes, and Cardiovascular Disease to Assess Eligibility for Sodium–Glucose Cotransporter 2 Inhibitors or Glucagon-Like Peptide 1 Receptor Agonists as First-Line Monotherapy (or Add-on to Metformin Monotherapy) in Type 2 Diabetes in Scotland
- (2020) Thomas M. Caparrotta et al. DIABETES CARE
- Sodium–glucose co‐transporter 2 inhibitors in heart failure: beyond glycaemic control. The position paper of the Heart Failure Association of the European Society of Cardiology
- (2020) Petar M. Seferović et al. EUROPEAN JOURNAL OF HEART FAILURE
- Empagliflozin decreases the plasma concentration of plasminogen activator inhibitor-1 (PAI-1) in patients with type 2 diabetes: Association with improvement of fibrinolysis
- (2020) Shintaro Sakurai et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Renal outcomes of SGLT2 inhibitors and GLP1 agonists in clinical practice
- (2020) Annemarie B. van der Aart-van der Beek et al. Nature Reviews Nephrology
- Empagliflozin protects heart from inflammation and energy depletion via AMPK activation
- (2020) Chintan N. Koyani et al. PHARMACOLOGICAL RESEARCH
- Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study
- (2020) Shun Kohsaka et al. Lancet Diabetes & Endocrinology
- Cardiovascular outcomes of type 2 diabetic patients treated with SGLT-2 inhibitors versus GLP-1 receptor agonists in real-life
- (2020) Enrico Longato et al. BMJ Open Diabetes Research & Care
- Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
- (2020) Milton Packer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dapagliflozin in Patients with Chronic Kidney Disease
- (2020) Hiddo J.L. Heerspink et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes
- (2020) Christopher P. Cannon et al. NEW ENGLAND JOURNAL OF MEDICINE
- The cost effectiveness of REACH-HF and home-based cardiac rehabilitation compared with the usual medical care for heart failure with reduced ejection fraction: A decision model-based analysis
- (2019) Rod S Taylor et al. European Journal of Preventive Cardiology
- 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease
- (2019) Donna K. Arnett et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Sub analysis of a clinical trial
- (2019) Agnes Bosch et al. Cardiovascular Diabetology
- A Big Win for Diabetic Kidney Disease: CREDENCE
- (2019) David Z.I. Cherney et al. Cell Metabolism
- Effect of Health Information Technologies on Cardiovascular Risk Factors among Patients with Diabetes
- (2019) Yilin Yoshida et al. Current Diabetes Reports
- CARMELINA®: an important piece of the DPP-4 inhibitor CVOT puzzle
- (2019) Guntram Schernthaner et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
- (2019) Vlado Perkovic et al. NEW ENGLAND JOURNAL OF MEDICINE
- 1477-P: Insights from Type 2 Diabetes Patients Suggest Need for Cardiovascular Health Education
- (2019) KEATON C. STONER et al. DIABETES
- 1247-P: Anticipating the Impact of 2019 Guidelines: Use of SGLT2i and GLP-1RA in Patients with Diabetes and Cardiovascular Disease
- (2019) CORI R. RATTELMAN et al. DIABETES
- 1193-P: Health-Care Costs and Medication Burden in Routine Care Initiators of Empagliflozin: A First Analysis from the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Study
- (2019) AJINKYA PAWAR et al. DIABETES
- Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial
- (2019) Hertzel C Gerstein et al. LANCET
- Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
- (2019) Hertzel C Gerstein et al. LANCET
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2019) Mansoor Husain et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lifetime benefits of early detection and treatment of diabetic kidney disease
- (2019) Julia Thornton Snider et al. PLoS One
- PDB126 COMPARATIVE HEALTHCARE COSTS AND MEDICATION BURDEN IN REAL-WORLD PATIENTS AUGMENTING METFORMIN MONOTHERAPY WITH EMPAGLIFLOZIN FROM THE EMPAGLIFLOZIN COMPARATIVE EFFECTIVENESS AND SAFETY (EMPRISE) STUDY
- (2019) A. Pawar et al. VALUE IN HEALTH
- PDB128 REDUCED HEALTHCARE UTILIZATION IN PATIENTS USING EMPAGLIFLOZIN: AN INTERIM ANALYSIS FROM THE EMPAGLIFLOZIN COMPARATIVE EFFECTIVENESS AND SAFETY (EMPRISE) STUDY
- (2019) M. Najafzadeh et al. VALUE IN HEALTH
- SGLT2 inhibitors in T2D and associated comorbidities — differentiating within the class
- (2019) Guntram Schernthaner et al. BMC Endocrine Disorders
- Trends in Antidiabetic Utilization and Expenditure in Denmark: A 22‐Year Nationwide Study
- (2019) Camilla Bang et al. DIABETES OBESITY & METABOLISM
- 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD
- (2019) Francesco Cosentino et al. EUROPEAN HEART JOURNAL
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
- (2019) John J.V. McMurray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial
- (2019) Ofri Mosenzon et al. Lancet Diabetes & Endocrinology
- Efficacy and safety of empagliflozin in older patients in the EMPA-REG OUTCOME® trial
- (2019) Pedro Monteiro et al. AGE AND AGEING
- Active participation of patients with type 2 diabetes in consultations with their primary care practice nurses – what helps and what hinders: a qualitative study
- (2019) E. du Pon et al. BMC HEALTH SERVICES RESEARCH
- P5003Reduced healthcare utilization in routine care initiators of empagliflozin with and without heart failure: interim analysis from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study
- (2019) A Pawar et al. EUROPEAN HEART JOURNAL
- Impact of Cardio-Renal-Metabolic Comorbidities on Cardiovascular Outcomes and Mortality in Type 2 Diabetes Mellitus
- (2019) David Z.I. Cherney et al. AMERICAN JOURNAL OF NEPHROLOGY
- Empagliflozin reduces the levels of CD36 and cardiotoxic lipids while improving autophagy in the hearts of Zucker diabetic fatty rats
- (2019) Alana Aragón-Herrera et al. BIOCHEMICAL PHARMACOLOGY
- 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2020
- (2019) DIABETES CARE
- 2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2019) John B. Buse et al. DIABETOLOGIA
- Comments on the 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases
- (2019) Anders Jorsal et al. EUROPEAN HEART JOURNAL
- Real-world comparison of hospitalization costs for heart failure in type 2 diabetes mellitus patients with established cardiovascular disease treated with canagliflozin versus other antihyperglycemic agents
- (2019) Yen-Wen Chen et al. JOURNAL OF MEDICAL ECONOMICS
- Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study
- (2019) Hiddo J L Heerspink et al. Lancet Diabetes & Endocrinology
- Patterns of glucose-lowering medication use in patients with type 2 diabetes and heart failure. Insights from the Diabetes Collaborative Registry (DCR)
- (2018) Suzanne V. Arnold et al. AMERICAN HEART JOURNAL
- Cost-of-illness studies in heart failure: a systematic review 2004–2016
- (2018) Wladimir Lesyuk et al. BMC Cardiovascular Disorders
- Are We Ready to Bell The Cat?
- (2018) Michael E. Nassif et al. CIRCULATION
- Weight Management in Patients with Type 2 Diabetes: a Multidisciplinary Real-world Approach
- (2018) Osama Hamdy et al. Current Diabetes Reports
- Cardiovascular Outcomes and Mortality in Type 2 Diabetes with Associated Cardio-Renal-Metabolic Comorbidities
- (2018) SUZANNE V. ARNOLD et al. DIABETES
- Renal Outcomes in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL)
- (2018) M. ANGELYN BETHEL et al. DIABETES
- Clinical Inertia in Type 2 Diabetes Management: Evidence From a Large, Real-World Data Set
- (2018) Kevin M. Pantalone et al. DIABETES CARE
- Health Care Costs Associated With Incident Complications in Patients With Type 2 Diabetes in Germany
- (2018) Katharina Kähm et al. DIABETES CARE
- Burden of cardio-renal-metabolic conditions in adults with type 2 diabetes within the Diabetes Collaborative Registry
- (2018) Suzanne V. Arnold et al. DIABETES OBESITY & METABOLISM
- Diabetes in the older patient: heterogeneity requires individualisation of therapeutic strategies
- (2018) Guntram Schernthaner et al. DIABETOLOGIA
- Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits
- (2018) Beatrice C. Lupsa et al. DIABETOLOGIA
- The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure
- (2018) Merlin C. Thomas et al. DIABETOLOGIA
- Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs
- (2018) Mikhail Kosiborod et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Clinical inertia versus overtreatment in glycaemic management
- (2018) Kamlesh Khunti et al. Lancet Diabetes & Endocrinology
- Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials
- (2018) Vlado Perkovic et al. Lancet Diabetes & Endocrinology
- Cardiovascular benefit in the limelight: shifting type 2 diabetes treatment paradigm towards early combination therapy in patients with overt cardiovascular disease
- (2018) Naim Shehadeh et al. Cardiovascular Diabetology
- Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2018) Aidin Rawshani et al. NEW ENGLAND JOURNAL OF MEDICINE
- Glucagon-like peptide-1 receptor action in the vasculature
- (2018) Malak Almutairi et al. PEPTIDES
- Addressing Clinical Inertia in Type 2 Diabetes Mellitus: A Review
- (2018) Jennifer Okemah et al. ADVANCES IN THERAPY
- Semaglutide Treatment and Renal Function in the SUSTAIN 6 Trial
- (2018) Irene Hramiak et al. Canadian Journal of Diabetes
- Unrecognised cardiovascular disease in type 2 diabetes: is it time to act earlier?
- (2018) Guntram Schernthaner et al. Cardiovascular Diabetology
- GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data
- (2018) Andrei C. Sposito et al. Cardiovascular Diabetology
- Changing the care pathway for Type 2 diabetes at the time of diagnosis: the role of the multidisciplinary team
- (2018) M. B. Whyte et al. DIABETIC MEDICINE
- Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2018) Melanie J. Davies et al. DIABETOLOGIA
- Type 2 diabetes in patients with end-stage kidney disease: influence on cardiovascular disease-related mortality risk
- (2018) Wai H Lim et al. MEDICAL JOURNAL OF AUSTRALIA
- Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
- (2018) Stephen D. Wiviott et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical inertia, reverse clinical inertia, and medication non-adherence in type 2 diabetes
- (2018) D. Giugliano et al. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
- Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
- (2017) Rury R. Holman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Renal Outcomes in Type 2 Diabetes
- (2017) Johannes F.E. Mann et al. NEW ENGLAND JOURNAL OF MEDICINE
- SGLT2 Inhibitors: A Systematic Review of Diabetic Ketoacidosis and Related Risk Factors in the Primary Literature
- (2017) Kelly R. Burke et al. PHARMACOTHERAPY
- Knowledge of risk factors for diabetes or cardiovascular disease (CVD) is poor among individuals with risk factors for CVD
- (2017) Monique F. Kilkenny et al. PLoS One
- Real-world use and modeled impact of glucose-lowering therapies evaluated in recent cardiovascular outcomes trials: An NCDR® Research to Practice project
- (2017) Suzanne V Arnold et al. European Journal of Preventive Cardiology
- Clinical inertia—Time to reappraise the terminology?
- (2017) Kamlesh Khunti et al. Primary Care Diabetes
- Clinical inertia to insulin initiation and intensification in the UK: A focused literature review
- (2017) Kamlesh Khunti et al. Primary Care Diabetes
- The Need Associated with Diabetes Primary Care and the Impact of Referral to a Specialist-Centered Multidisciplinary Diabetes Program (the NADIR Study)
- (2016) Harpreet S. Bajaj et al. Canadian Journal of Diabetes
- SGLT2 Inhibitors: Benefit/Risk Balance
- (2016) André J. Scheen Current Diabetes Reports
- A systematic review of interventions targeting primary care or community based professionals on cardio-metabolic risk factor control in people with diabetes
- (2016) S. Seidu et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- DOES CLINICAL INERTIA VARY BY PERSONALIZED A1C GOAL? A STUDY OF PREDICTORS AND PREVALENCE OF CLINICAL INERTIA IN A U.S. MANAGED-CARE SETTING
- (2016) Jay Lin et al. Endocrine Practice
- Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME®trial
- (2016) David Fitchett et al. EUROPEAN HEART JOURNAL
- Communication and patient participation influencing patient recall of treatment discussions
- (2016) Claude Richard et al. HEALTH EXPECTATIONS
- Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
- (2016) Christoph Wanner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Impact of Empagliflozin (Jardiance) to the NHS: Estimation of Budget and Event Impact Based on Empa-Reg Outcome Data
- (2016) I Daacke et al. VALUE IN HEALTH
- Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 Inhibitors
- (2015) Julio Rosenstock et al. DIABETES CARE
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- United States Renal Data System public health surveillance of chronic kidney disease and end-stage renal disease
- (2015) Allan J. Collins et al. Kidney International Supplements
- Primary Care Detection of Chronic Kidney Disease in Adults with Type-2 Diabetes: The ADD-CKD Study (Awareness, Detection and Drug Therapy in Type 2 Diabetes and Chronic Kidney Disease)
- (2014) Lynda A. Szczech et al. PLoS One
- Clinical Inertia in Individualising Care for Diabetes: Is There Time to do More in Type 2 Diabetes?
- (2014) William David Strain et al. Diabetes Therapy
- Barriers and Potential Solutions to Providing Optimal Guideline-Driven Care to Patients With Diabetes in the U.S.
- (2013) R. A. Vigersky et al. DIABETES CARE
- Computerized Decision Support Systems in Primary Care for Type 2 Diabetes Patients Only Improve Patients' Outcomes when Combined with Feedback on Performance and Case Management: A Systematic Review
- (2013) Frits G.W. Cleveringa et al. Diabetes Technology & Therapeutics
- Non-adherence to diabetes guidelines in primary care – The enemy of evidence-based practice
- (2012) Samuel Seidu et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Estimating the financial cost of chronic kidney disease to the NHS in England
- (2012) Marion Kerr et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Diabetic Cardiovascular Disease Predicts Chronic Kidney Disease Awareness in the Kidney Early Evaluation Program
- (2011) Adam Whaley-Connell et al. CardioRenal Medicine
- Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis
- (2010) G. Schernthaner et al. DIABETOLOGIA
- Estimated glomerular filtration rate and albuminuria are independent predictors of cardiovascular events and death in type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study
- (2010) P. L. Drury et al. DIABETOLOGIA
- Diabetes Mellitus and CKD Awareness: The Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES)
- (2009) Adam Whaley-Connell et al. AMERICAN JOURNAL OF KIDNEY DISEASES
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now